Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Summary Are you ready to help shape the future of neuroscience across Europe? As Regional Disease Area Lead, Neuroscience, you will play a key role in driving disease area performance, strengthening competitive execution, and preparing markets